Hormone replacement therapy used for correction of menstrual dysfunction associated with liver pathology

Abstract

The problem of viral hepatitis and menstrual dysfunctions stays present, is determined by the high incidence and severity of physiopathological abnormalities, specific to these associations. In the Republic of Moldova, 9% of the population are chronic carriers of HVB, HVC affects 1.5-5% of the population. The purpose of this work was to study the therapeutic effect of hormone therapy in women with menstrual dysfunctions caused by chronic viral hepatitis. Materials and methods: The controlled randomized study evaluated the treatment results of 80 patients with menstrual dysfunctions in association with liver pathology, randomly picked out from 319 women suffering from chronic viral hepatitis. The selection of the hormonal therapy was made depending on the menstrual irregularities, hormonal profile and results of the genitals sonography: o 1st group (26 patients) – hepatoprotectors, o 2nd group (23 patients) – Didrogesteron 10 mg (Duphaston) + hepatoprotectors, o 3rd group (31 patients) – Etradiol 2mg + Didrogesteron 10 mg (Femoston) + hepatoprotectors. The control group included 15 healthy women of reproductive age with normal menstrual cycle. Results: The examined patient’s age varied between 18 and 40 years, mean age - 26.0±5 years. Bilirubin level in patients with HVB was 3 times higher compared with the control group but in mix-hepatitis -10 times. Transaminases were elevated 10-40 times, especially in mixed viral hepatitis. Alkaline phosphatase (27.81 ± 1.3 UI/l), prothrombin, total protein, and albumin were considerably decreased. Similar changes have been observed in cholesterol level (dropped till 2.60±0.21 mmol/l) and β-lipoprotein (195.0 ± 25.3 Un), which are evidently decreased in all patients with all types of viral hepatitis. Regular menstrual cycle was present only in 7.5 ± 2.48.